The significance of expression proliferation factors and cell cycle regulation proteins in giant cell tumor of bone

Gigantocelularni tumor kosti (GCTB) je primarni koštani tumor koga karakteriše prisustvo dve ćelijske populacije: džinovske ćelije tipa osteoklasta i monojedarne stromalne ćelije koje predstavljaju pravu neoplastičnu tumorsku komponentu. Biološko ponašanje GCTB je nepredvidivo. Terapija izbora za gigantocelularni tumor kosti je hirurška. Međutim, pojava recidiva nakon hirurške intervencije je opisana kod značajnog broja pacijenata i kreće se od 10 do 25%. Postoji veliki broj studija koje se bave analizom biološkog ponašanja GCTB, pre svega sa ciljem predviđanja nastanka recidiva. One su veoma značajne jer ukazuju da GCTB sa agresivnijim biološkim ponašanjem zahteva i agresivniji terapijski pristup. Naše istraživanje se odnosi na određivanje različitih kliničko-radiološko-patohistoloških parametara koji bi mogli uticati na predikciju biološkog ponašanja GCTB, odnosno predviđanje pojave recidiva. Izdvajanjem i jasnim definisanjem karakteristika tumora koje bi mogle ukazivati na povećan rizik za ponovnu pojavu GCTB, nakon hirurške terapije, moglo bi eventualno opravdati i ekstenzivnost/agresivnost terapijskog pristupa. Ciljevi: Gigantocelularni tumor kosti je benigni tumor, koji i danas ima nepredvidljivo ponašanje, morfološko i kliničko. U cilju preciznijeg utvrđivanja ponašanja tumora i utvđivanja novih prognostičkih faktora, postavili smo sledeće ciljeve: 1. Utvrđivanje korelacije ekspresije Ki-67, p53 i Ciklin D1 u tkivu gigantocelularnog tumora kosti sa biološkim ponašanjem ovog tumora (pojavom rest-recidiva ili pojavom plućnih metastaza). 2. Utvrđivanje korelacije ekspresije Ki-67, p53 i Ciklin D1 u tkivu gigantocelularnog tumora kosti sa kliničko-patološkim prognostičkim parametrima (klinička GTM, Enneking-ova klasifikacija). Metodologija: Ova teza je izvedena kao studija preseka, u koju je uključeno 164 pacijenata kojima je u periodu od 1964-2008. god. na Institutu za patologiju Medicinskog fakulteta u Beogradu dijagnostikovan gigantocelularni tumor kosti, a koji su operisani na Institutu za Ortopedsko-hirurške bolesti „Banjica“. Kriterijumi za uključenje u studiju bili su: patohistološki verifikovan gigantocelularni tumor kosti...Giant cell tumor of bone (GCTB) is a primary bone tumor, characterized by the presence of two cell populations: osteoclast-like giant cells and mononuclear stromal cells, which are, in fact, the real neoplastic tumor component. Biological behavior of the GCTB is unpredictable. Apart from the locally aggressive growth followed by the destruction of bone tissue and propagation in the surrounding soft tissue, as well as frequent incidence of fractures and relapses, the occurrences of pulmonary metastases are also reported. The therapy of choice for giant cell tumor of bone is surgical. However, the recurrence after surgical intervention is found in significant number of patients, i.e. at a rate of 10 to 25%. A large number of studies deal with analyzing the biological behavior of GCTB, primarily in order to predict the recurrence. Those studies are of great importance, since they imply that GCTB with a more aggressive biological behavior also requires a more aggressive therapeutic approach. Our research refers to determining various clinical, radiological and pathohistological parameters which may have an influence on predicting the biological behavior of GCTB, i.e. on predicting the incidence of relapses. Detecting and clearly defining the tumor characteristics which could indicate an increased risk of GCTB recurrence after surgical therapy might account for the extensiveness/aggressiveness of therapeutic approach. Objective: Giant Cell Tumor of Bone is a benign tumor, which still has an unpredictable behavior, morphology and clinical. In order to precisely determine the behavior of the tumor and the determining of new prognostic factors, we set the following objectives: 1. Establishing correlations expression Ki-67, p53 and Cyclin D1 in the tissues of giant cell tumor of bone with the biological behavior of this tumor (the appearance of rest-relapse or emergence of pulmonary metastases). 2. Establishing correlations expression of Ki-67, p53 and Cyclin D1 in the tissues of giant cell tumor of bone with clinicopathological prognostic parameters (clinical GTM, Enneking's classification)..

Skeletal Manifestations of Hydatid Disease in Serbia: Demographic Distribution, Site Involvement, Radiological Findings, and Complications

Although Serbia is recognized as an endemic country for echinococcosis, no information about precise incidence in humans has been available. The aim of this study was to investigate the skeletal manifestations of hydatid disease in Serbia. This retrospective study was conducted by reviewing the medical database of Institute for Pathology (Faculty of Medicine in Belgrade), a reference institution for bone pathology in Serbia. We reported a total of 41 patients with bone cystic echinococcosis (CE) during the study period. The mean age of 41 patients was 40.9 +/- 18.8 years. In 39% of patients, the fracture line was the only visible radiological sign, followed by cyst and tumefaction. The spine was the most commonly involved skeletal site (55.8%), followed by the femur (18.6%), pelvis (13.9%), humerus (7.0%), rib (2.3%), and tibia (2.3%). Pain was the symptom in 41.5% of patients, while some patients demonstrated complications such as paraplegia (22.0%), pathologic fracture (48.8%), and scoliosis (9.8%). The pathological fracture most frequently affected the spine (75.0%) followed by the femur (20.0%) and tibia (5.0%). However, 19.5% of patients didn't develop any complication or symptom. In this study, we showed that bone CE is not uncommon in Serbian population. As reported in the literature, therapy of bone CE is controversial and its results are poor. In order to improve the therapy outcome, early diagnosis, before symptoms and complications occur, can be contributive

The significance of expression proliferation factors and cell cycle regulation proteins in giant cell tumor of bone

Gigantocelularni tumor kosti (GCTB) je primarni koštani tumor koga karakteriše prisustvo dve ćelijske populacije: džinovske ćelije tipa osteoklasta i monojedarne stromalne ćelije koje predstavljaju pravu neoplastičnu tumorsku komponentu. Biološko ponašanje GCTB je nepredvidivo. Terapija izbora za gigantocelularni tumor kosti je hirurška. Međutim, pojava recidiva nakon hirurške intervencije je opisana kod značajnog broja pacijenata i kreće se od 10 do 25%. Postoji veliki broj studija koje se bave analizom biološkog ponašanja GCTB, pre svega sa ciljem predviđanja nastanka recidiva. One su veoma značajne jer ukazuju da GCTB sa agresivnijim biološkim ponašanjem zahteva i agresivniji terapijski pristup. Naše istraživanje se odnosi na određivanje različitih kliničko-radiološko-patohistoloških parametara koji bi mogli uticati na predikciju biološkog ponašanja GCTB, odnosno predviđanje pojave recidiva. Izdvajanjem i jasnim definisanjem karakteristika tumora koje bi mogle ukazivati na povećan rizik za ponovnu pojavu GCTB, nakon hirurške terapije, moglo bi eventualno opravdati i ekstenzivnost/agresivnost terapijskog pristupa. Ciljevi: Gigantocelularni tumor kosti je benigni tumor, koji i danas ima nepredvidljivo ponašanje, morfološko i kliničko. U cilju preciznijeg utvrđivanja ponašanja tumora i utvđivanja novih prognostičkih faktora, postavili smo sledeće ciljeve: 1. Utvrđivanje korelacije ekspresije Ki-67, p53 i Ciklin D1 u tkivu gigantocelularnog tumora kosti sa biološkim ponašanjem ovog tumora (pojavom rest-recidiva ili pojavom plućnih metastaza). 2. Utvrđivanje korelacije ekspresije Ki-67, p53 i Ciklin D1 u tkivu gigantocelularnog tumora kosti sa kliničko-patološkim prognostičkim parametrima (klinička GTM, Enneking-ova klasifikacija). Metodologija: Ova teza je izvedena kao studija preseka, u koju je uključeno 164 pacijenata kojima je u periodu od 1964-2008. god. na Institutu za patologiju Medicinskog fakulteta u Beogradu dijagnostikovan gigantocelularni tumor kosti, a koji su operisani na Institutu za Ortopedsko-hirurške bolesti „Banjica“. Kriterijumi za uključenje u studiju bili su: patohistološki verifikovan gigantocelularni tumor kosti...Giant cell tumor of bone (GCTB) is a primary bone tumor, characterized by the presence of two cell populations: osteoclast-like giant cells and mononuclear stromal cells, which are, in fact, the real neoplastic tumor component. Biological behavior of the GCTB is unpredictable. Apart from the locally aggressive growth followed by the destruction of bone tissue and propagation in the surrounding soft tissue, as well as frequent incidence of fractures and relapses, the occurrences of pulmonary metastases are also reported. The therapy of choice for giant cell tumor of bone is surgical. However, the recurrence after surgical intervention is found in significant number of patients, i.e. at a rate of 10 to 25%. A large number of studies deal with analyzing the biological behavior of GCTB, primarily in order to predict the recurrence. Those studies are of great importance, since they imply that GCTB with a more aggressive biological behavior also requires a more aggressive therapeutic approach. Our research refers to determining various clinical, radiological and pathohistological parameters which may have an influence on predicting the biological behavior of GCTB, i.e. on predicting the incidence of relapses. Detecting and clearly defining the tumor characteristics which could indicate an increased risk of GCTB recurrence after surgical therapy might account for the extensiveness/aggressiveness of therapeutic approach. Objective: Giant Cell Tumor of Bone is a benign tumor, which still has an unpredictable behavior, morphology and clinical. In order to precisely determine the behavior of the tumor and the determining of new prognostic factors, we set the following objectives: 1. Establishing correlations expression Ki-67, p53 and Cyclin D1 in the tissues of giant cell tumor of bone with the biological behavior of this tumor (the appearance of rest-relapse or emergence of pulmonary metastases). 2. Establishing correlations expression of Ki-67, p53 and Cyclin D1 in the tissues of giant cell tumor of bone with clinicopathological prognostic parameters (clinical GTM, Enneking's classification)..

The significance of expression proliferation factors and cell cycle regulation proteins in giant cell tumor of bone

Gigantocelularni tumor kosti (GCTB) je primarni koštani tumor koga karakteriše prisustvo dve ćelijske populacije: džinovske ćelije tipa osteoklasta i monojedarne stromalne ćelije koje predstavljaju pravu neoplastičnu tumorsku komponentu. Biološko ponašanje GCTB je nepredvidivo. Terapija izbora za gigantocelularni tumor kosti je hirurška. Međutim, pojava recidiva nakon hirurške intervencije je opisana kod značajnog broja pacijenata i kreće se od 10 do 25%. Postoji veliki broj studija koje se bave analizom biološkog ponašanja GCTB, pre svega sa ciljem predviđanja nastanka recidiva. One su veoma značajne jer ukazuju da GCTB sa agresivnijim biološkim ponašanjem zahteva i agresivniji terapijski pristup. Naše istraživanje se odnosi na određivanje različitih kliničko-radiološko-patohistoloških parametara koji bi mogli uticati na predikciju biološkog ponašanja GCTB, odnosno predviđanje pojave recidiva. Izdvajanjem i jasnim definisanjem karakteristika tumora koje bi mogle ukazivati na povećan rizik za ponovnu pojavu GCTB, nakon hirurške terapije, moglo bi eventualno opravdati i ekstenzivnost/agresivnost terapijskog pristupa. Ciljevi: Gigantocelularni tumor kosti je benigni tumor, koji i danas ima nepredvidljivo ponašanje, morfološko i kliničko. U cilju preciznijeg utvrđivanja ponašanja tumora i utvđivanja novih prognostičkih faktora, postavili smo sledeće ciljeve: 1. Utvrđivanje korelacije ekspresije Ki-67, p53 i Ciklin D1 u tkivu gigantocelularnog tumora kosti sa biološkim ponašanjem ovog tumora (pojavom rest-recidiva ili pojavom plućnih metastaza). 2. Utvrđivanje korelacije ekspresije Ki-67, p53 i Ciklin D1 u tkivu gigantocelularnog tumora kosti sa kliničko-patološkim prognostičkim parametrima (klinička GTM, Enneking-ova klasifikacija). Metodologija: Ova teza je izvedena kao studija preseka, u koju je uključeno 164 pacijenata kojima je u periodu od 1964-2008. god. na Institutu za patologiju Medicinskog fakulteta u Beogradu dijagnostikovan gigantocelularni tumor kosti, a koji su operisani na Institutu za Ortopedsko-hirurške bolesti „Banjica“. Kriterijumi za uključenje u studiju bili su: patohistološki verifikovan gigantocelularni tumor kosti...Giant cell tumor of bone (GCTB) is a primary bone tumor, characterized by the presence of two cell populations: osteoclast-like giant cells and mononuclear stromal cells, which are, in fact, the real neoplastic tumor component. Biological behavior of the GCTB is unpredictable. Apart from the locally aggressive growth followed by the destruction of bone tissue and propagation in the surrounding soft tissue, as well as frequent incidence of fractures and relapses, the occurrences of pulmonary metastases are also reported. The therapy of choice for giant cell tumor of bone is surgical. However, the recurrence after surgical intervention is found in significant number of patients, i.e. at a rate of 10 to 25%. A large number of studies deal with analyzing the biological behavior of GCTB, primarily in order to predict the recurrence. Those studies are of great importance, since they imply that GCTB with a more aggressive biological behavior also requires a more aggressive therapeutic approach. Our research refers to determining various clinical, radiological and pathohistological parameters which may have an influence on predicting the biological behavior of GCTB, i.e. on predicting the incidence of relapses. Detecting and clearly defining the tumor characteristics which could indicate an increased risk of GCTB recurrence after surgical therapy might account for the extensiveness/aggressiveness of therapeutic approach. Objective: Giant Cell Tumor of Bone is a benign tumor, which still has an unpredictable behavior, morphology and clinical. In order to precisely determine the behavior of the tumor and the determining of new prognostic factors, we set the following objectives: 1. Establishing correlations expression Ki-67, p53 and Cyclin D1 in the tissues of giant cell tumor of bone with the biological behavior of this tumor (the appearance of rest-relapse or emergence of pulmonary metastases). 2. Establishing correlations expression of Ki-67, p53 and Cyclin D1 in the tissues of giant cell tumor of bone with clinicopathological prognostic parameters (clinical GTM, Enneking's classification)..